PHARM Pharming Group N.V.

Price Chart

Executive Summary

Pharming Group reported Q1 2026 total revenues of $72.4M, an 8% decline YoY, driven by a 15% drop in RUCONEST® revenue ($58.4M) due to inventory drawdowns and market exits. Joenja® revenue grew 34% to $14.1M, and the company reaffirmed full-year 2026 revenue guidance of $405M-$425M (8%-13% growth). The net loss narrowed to $5.2M from $14.9M a year ago, and operating cash flow turned positive at $2.0M.

Key Financial Metrics

Actionable Insight

Key Facts

• Q1 2026 total revenues $72.4M, down 8% YoY from $79.1M
• RUCONEST® revenue $58.4M, down 15% YoY due to inventory drawdowns and non-U.S. market exit
• Joenja® revenue $14.1M, up 34% YoY, driven by U.S. patient growth (127 on paid therapy, +25% YoY)
• Net loss narrowed to $5.2M from $14.9M in Q1 2025
• Positive net cash flow from operations of $2.0M vs $0.2M in prior year
• Reaffirmed FY2026 revenue guidance $405M-$425M (8%-13% growth)
• Joenja® approved in Japan for APDS patients aged 4+; positive CHMP opinion in Europe
• Resubmitted pediatric sNDA to FDA for Joenja® 40mg/50mg doses; additional sNDA planned for summer
• Cash and equivalents $171.8M at quarter end, down from $181.1M due to $12.3M lease settlement

Financial Impact

Revenue decline of $6.6M YoY (8%) with net loss improvement of $9.7M; positive operating cash flow of $2.0M

Risk Factors

• Continued RUCONEST® revenue decline from competitive dynamics and market exit
• FDA CRL on pediatric sNDA for Joenja® could delay label expansion
• Pipeline execution risk for napazimone (KL1333) and leniolisib Phase II trials
• Currency translation losses ($5.0M OCI loss in Q1) impacting reported results

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

US Market Status

Related Tickers